PE firms eyeing Perrigo pharma business

|About: Aclaris Therapeutics, ... (ACRS)|By:, SA News Editor

Private equity shops Apollo Global Management and CVC Capital Partners are apparently bidding for Perrigo's (PRGO +2.6%) generic pharmaceuticals unit according to informed sources who add that the business could fetch more than $2.5B.

The news seems to have stoked an uptick in buying in other generics players.

Selected tickers: Akorn (AKRX +0.9%); ANI Pharmaceuticals (ANIP +1.3%); Amphastar Pharmaceuticals (AMPH +1.9%); Coherus BioSciences (CHRS +0.7%); Collegium Pharmaceutical (COLL +1.3%); Mallinckrodt (MNK +2.1%); Teva Pharmaceutical Industries (TEVA +1.7%); Lannett Company (LCI +0.4%); Mylan (MYL +1.5%); Aclaris Therapeutics (ACRS +0.2%); Endo International (ENDP +0.1%)

Subscribe for full text news in your inbox